297 related articles for article (PubMed ID: 36422706)
1. International Consensus Classification of acute lymphoblastic leukemia/lymphoma.
Duffield AS; Mullighan CG; Borowitz MJ
Virchows Arch; 2023 Jan; 482(1):11-26. PubMed ID: 36422706
[TBL] [Abstract][Full Text] [Related]
2. Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
Davis K; Sheikh T; Aggarwal N
Semin Diagn Pathol; 2023 May; 40(3):202-215. PubMed ID: 37120350
[TBL] [Abstract][Full Text] [Related]
3. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
4. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
Angelova E; Audette C; Kovtun Y; Daver N; Wang SA; Pierce S; Konoplev SN; Khogeer H; Jorgensen JL; Konopleva M; Zweidler-McKay PA; Medeiros LJ; Kantarjian HM; Jabbour EJ; Khoury JD
Haematologica; 2019 Apr; 104(4):749-755. PubMed ID: 30361418
[TBL] [Abstract][Full Text] [Related]
5. Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis.
Kovach AE; Wood BL
Semin Diagn Pathol; 2023 Nov; 40(6):457-471. PubMed ID: 37953192
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
7. Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.
Wenzinger C; Williams E; Gru AA
Curr Hematol Malig Rep; 2018 Aug; 13(4):275-288. PubMed ID: 29951888
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.
Yenamandra AK; Kaviany S; Borinstein SC; Friedman DL; Kovach AE
Lab Med; 2019 Oct; 50(4):401-405. PubMed ID: 30938769
[TBL] [Abstract][Full Text] [Related]
9. Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma.
Lee WJ; Moon HR; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
J Am Acad Dermatol; 2014 Feb; 70(2):318-25. PubMed ID: 24314877
[TBL] [Abstract][Full Text] [Related]
10. Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan.
Halahleh K; Muradi I; Khalil MZ; Halahleh L; Sughayer M; Kamal N; Sultan I; Alrabi K
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e411-e419. PubMed ID: 37730482
[TBL] [Abstract][Full Text] [Related]
11. Highly aggressive lymphomas in adults.
Sweetenham JW
Hematol Oncol Clin North Am; 2008 Oct; 22(5):965-78, ix. PubMed ID: 18954746
[TBL] [Abstract][Full Text] [Related]
12. B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
Fang H; Wang W; El Hussein S; Morita K; Beird HC; Mitra A; Loghavi S; Lin P; Jabbour EJ; Khoury JD
Br J Haematol; 2021 Sep; 194(6):1034-1038. PubMed ID: 34402058
[TBL] [Abstract][Full Text] [Related]
13. Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients.
Xu J; Zhao L
J Pediatr Hematol Oncol; 2023 May; 45(4):189-194. PubMed ID: 35973104
[TBL] [Abstract][Full Text] [Related]
14. Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia.
McGregor S; McNeer J; Gurbuxani S
Semin Diagn Pathol; 2012 Feb; 29(1):2-11. PubMed ID: 22372201
[TBL] [Abstract][Full Text] [Related]
15.
Jain S; Abraham A
Arch Pathol Lab Med; 2020 Feb; 144(2):150-155. PubMed ID: 31644323
[TBL] [Abstract][Full Text] [Related]
16. Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia.
Walter W; Shahswar R; Stengel A; Meggendorfer M; Kern W; Haferlach T; Haferlach C
BMC Cancer; 2021 Aug; 21(1):886. PubMed ID: 34340673
[TBL] [Abstract][Full Text] [Related]
17. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma.
DuVall AS; Wesevich A; Larson RA
Curr Hematol Malig Rep; 2023 Dec; 18(6):217-225. PubMed ID: 37490229
[TBL] [Abstract][Full Text] [Related]
18. Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups - a UKALLXII study.
Rai L; Casanova A; Moorman AV; Richards S; Buck G; Goldstone AH; Fielding AK; Foroni L
Br J Haematol; 2010 Feb; 148(3):394-401. PubMed ID: 19895613
[TBL] [Abstract][Full Text] [Related]
19. p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.
Davies C; Hogarth LA; Mackenzie KL; Hall AG; Lock RB
Cell Cycle; 2015; 14(22):3602-12. PubMed ID: 26506264
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL.
Onishi Y; Furukawa E; Kamata M; Fukatsu M; Kameoka Y; Hatta S; Hamada H; Oyake T; Kai T; Sukegawa M; Nakajima S; Yanagiya R; Yamaguchi K; Takahashi T; Harazaki Y; Izumi T; Murai K; Ito S; Ikezoe T; Ishizawa K; Takahashi N; Harigae H
Int J Hematol; 2023 May; 117(5):738-747. PubMed ID: 36757523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
